Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.

Mirian C, Duun-Henriksen AK, Juratli T, Sahm F, Spiegl-Kreinecker S, Peyre M, Biczok A, Tonn JC, Goutagny S, Bertero L, Maier AD, Møller Pedersen M, Law I, Broholm H, Cahill DP, Brastianos P, Poulsgaard L, Fugleholm K, Ziebell M, Munch T, Mathiesen T.

J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):378-387. doi: 10.1136/jnnp-2019-322257. Epub 2020 Feb 10. Review.

PMID:
32041819
2.

Surface reconstruction from routine CT-scan shows large anatomical variations of falx cerebri and tentorium cerebelli.

Staquet H, Francois PM, Sandoz B, Laporte S, Decq P, Goutagny S.

Acta Neurochir (Wien). 2020 Feb 7. doi: 10.1007/s00701-020-04256-2. [Epub ahead of print]

PMID:
32034496
3.

More complications in cervical than in non-cervical spine tuberculosis.

Pourbaix A, Zarrouk V, Allaham W, Leflon V, Rousseau MA, Goutagny S, Guigui P, Fantin B.

Infect Dis (Lond). 2020 Mar;52(3):170-176. doi: 10.1080/23744235.2019.1690675. Epub 2019 Nov 13.

PMID:
31718363
4.

Biomarkers of Alzheimer's disease in older and oldest old patients.

Lilamand M, Cognat E, Goutagny S, Hourregue C, Hugon J, Dumurgier J, Paquet C.

Geriatr Psychol Neuropsychiatr Vieil. 2019 Mar 1;17(1):65-72. doi: 10.1684/pnv.2019.0779. Review.

PMID:
30907369
5.

Hemorrhagic presentation of frontal partially calcified pilocytic astrocytoma in an 18-year-old woman: A case report and literature review as "clinical case".

Boukobza M, Goutagny S, Cazals-Hatem D, Laissy JP.

Neurochirurgie. 2019 Feb;65(1):32-35. doi: 10.1016/j.neuchi.2018.12.002. Epub 2019 Jan 30.

PMID:
30711258
6.

The molecular landscape of glioma in patients with Neurofibromatosis 1.

D'Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A.

Nat Med. 2019 Jan;25(1):176-187. doi: 10.1038/s41591-018-0263-8. Epub 2018 Dec 10.

7.

Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders.

Paquet C, Bouaziz-Amar E, Cognat E, Volpe-Gillot L, Haddad V, Mahieux F, Dekimeche S, Defontaines B, Chabriat H, Belin C, Texeira A, Goutagny S, Questel F, Azuar J, Sellier PO, Laplanche JL, Hugon J, Dumurgier J.

J Alzheimers Dis. 2018;64(3):889-897. doi: 10.3233/JAD-180240.

PMID:
29966201
8.

Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.

Louvrier C, Pasmant E, Briand-Suleau A, Cohen J, Nitschké P, Nectoux J, Orhant L, Zordan C, Goizet C, Goutagny S, Lallemand D, Vidaud M, Vidaud D, Kalamarides M, Parfait B.

Neuro Oncol. 2018 Jun 18;20(7):917-929. doi: 10.1093/neuonc/noy009.

9.

A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas.

Goutagny S, Giovannini M, Kalamarides M.

J Neurooncol. 2017 Jun;133(2):443-445. doi: 10.1007/s11060-017-2447-3. Epub 2017 Apr 22. No abstract available.

PMID:
28434114
10.

A 19-year-old male with a well-demarcated parieto-occipital mass.

Beaufrère A, Fouet M, Bruno O, Cazals-Hatem D, Goutagny S.

Brain Pathol. 2017 May;27(3):401-402. doi: 10.1111/bpa.12509. No abstract available.

PMID:
28414892
11.

Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.

Goutagny S, Kalamarides M.

Neurochirurgie. 2018 Nov;64(5):370-374. doi: 10.1016/j.neuchi.2016.09.004. Epub 2017 Feb 3.

PMID:
28162254
12.

Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.

Ouerdani A, Goutagny S, Kalamarides M, Trocóniz IF, Ribba B.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1263-73. doi: 10.1007/s00280-016-3046-2. Epub 2016 May 4.

PMID:
27146400
13.

PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss.

Peyre M, Salaud C, Clermont-Taranchon E, Niwa-Kawakita M, Goutagny S, Mawrin C, Giovannini M, Kalamarides M.

Oncotarget. 2015 Oct 20;6(32):32713-22. doi: 10.18632/oncotarget.5296.

14.

Neurofibromatosis type 2 French cohort analysis using a comprehensive NF2 molecular diagnostic strategy.

Pasmant E, Louvrier C, Luscan A, Cohen J, Laurendeau I, Vidaud M, Vidaud D, Goutagny S, Kalamarides M, Parfait B.

Neurochirurgie. 2018 Nov;64(5):335-341. doi: 10.1016/j.neuchi.2015.01.004. Epub 2015 Jun 12.

PMID:
26073919
15.

Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.

Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, Larroque B, Sterkers O, Giovannini M, Kalamarides M.

J Neurooncol. 2015 Apr;122(2):313-20. doi: 10.1007/s11060-014-1710-0. Epub 2015 Jan 8.

16.

Forestier's disease presenting with dysphagia and disphonia.

Najib J, Goutagny S, Peyre M, Faillot T, Kalamarides M.

Pan Afr Med J. 2014 Mar 6;17:168. doi: 10.11604/pamj.2014.17.168.2453. eCollection 2014.

17.

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, Fisher LM, Valeyrie-Allanore L, Wolkenstein P, Goutagny S, Kalamarides M.

Neuro Oncol. 2014 Apr;16(4):493-504. doi: 10.1093/neuonc/not242. Epub 2014 Jan 10.

18.

Recommendations for imaging tumor response in neurofibromatosis clinical trials.

Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, Fisher MJ, Goutagny S, Harris GJ, Jaramillo D, Karajannis MA, Korf BR, Mautner V, Plotkin SR, Poussaint TY, Robertson K, Shih CS, Widemann BC; REiNS International Collaboration.

Neurology. 2013 Nov 19;81(21 Suppl 1):S33-40. doi: 10.1212/01.wnl.0000435744.57038.af.

19.

High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.

Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M.

Brain Pathol. 2014 Mar;24(2):184-9. doi: 10.1111/bpa.12110. Epub 2013 Dec 23.

PMID:
24261697
20.

Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results.

Peyre M, Goutagny S, Bah A, Bernardeschi D, Larroque B, Sterkers O, Kalamarides M.

Neurosurgery. 2013 Jun;72(6):907-13; discussion 914; quiz 914. doi: 10.1227/NEU.0b013e31828bae28.

PMID:
23407292
21.

Neurofibromatosis type 2 in the elderly population: clinical and molecular features.

Goutagny S, Bah AB, Parfait B, Sterkers O, Kalamarides M.

Am J Med Genet A. 2013 Apr;161A(4):667-70. doi: 10.1002/ajmg.a.35851. Epub 2013 Jan 15.

PMID:
23322716
22.

Penetrating craniocerebral injury caused by a rubber bullet questions the relative harmlessness of these weapons.

Amelot A, Goutagny S, Ricome S, Peyre M.

Am J Emerg Med. 2013 Mar;31(3):636.e5-7. doi: 10.1016/j.ajem.2012.10.026. Epub 2012 Dec 4. No abstract available.

PMID:
23218133
23.

Increased growth rate of a WHO grade I ganglioglioma during pregnancy.

Knafo S, Goutagny S, Pallud J.

Br J Neurosurg. 2013 Feb;27(1):119-21. doi: 10.3109/02688697.2012.703356. Epub 2012 Jul 31.

PMID:
22844970
24.

Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features.

Goutagny S, Bah AB, Henin D, Parfait B, Grayeli AB, Sterkers O, Kalamarides M.

Neuro Oncol. 2012 Aug;14(8):1090-6. doi: 10.1093/neuonc/nos129. Epub 2012 Jun 18.

25.

Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2.

Peyre M, Goutagny S, Imbeaud S, Bozorg-Grayeli A, Felce M, Sterkers O, Kalamarides M.

Neuro Oncol. 2011 Oct;13(10):1125-32. doi: 10.1093/neuonc/nor101. Epub 2011 Jul 28.

26.

Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab.

Goutagny S, Raymond E, Sterkers O, Colombani JM, Kalamarides M.

Ann Oncol. 2011 Apr;22(4):990-1. doi: 10.1093/annonc/mdr012. Epub 2011 Feb 28. No abstract available.

27.

Meningiomas and neurofibromatosis.

Goutagny S, Kalamarides M.

J Neurooncol. 2010 Sep;99(3):341-7. doi: 10.1007/s11060-010-0339-x. Epub 2010 Aug 17. Review.

PMID:
20714782
28.

Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.

Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, Black PM, Giovannini M, Carroll RS, Kalamarides M.

Clin Cancer Res. 2010 Aug 15;16(16):4155-64. doi: 10.1158/1078-0432.CCR-10-0891. Epub 2010 Aug 3.

29.

[Neurofibromatosis type 2].

Goutagny S, Bouccara D, Bozorg-Grayeli A, Sterkers O, Kalamarides M.

Rev Neurol (Paris). 2007 Sep;163(8-9):765-77. Review. French.

PMID:
17878803
30.

[Meningiomas].

Kalamarides M, Goutagny S.

Rev Prat. 2006 Oct 31;56(16):1792-8. Review. French.

PMID:
17315505
31.

[Chronic intramedullary abscess (Streptococcus sanguis). A case report and review of the literature].

Seizeur R, Condette-Auliac S, Goutagny S, Pencalet P, Gaillard S.

Neurochirurgie. 2006 Dec;52(6):542-6. French.

PMID:
17203904
32.

Mutations within the MGC4607 gene cause cerebral cavernous malformations.

Denier C, Goutagny S, Labauge P, Krivosic V, Arnoult M, Cousin A, Benabid AL, Comoy J, Frerebeau P, Gilbert B, Houtteville JP, Jan M, Lapierre F, Loiseau H, Menei P, Mercier P, Moreau JJ, Nivelon-Chevallier A, Parker F, Redondo AM, Scarabin JM, Tremoulet M, Zerah M, Maciazek J, Tournier-Lasserve E; Société Française de Neurochirurgie.

Am J Hum Genet. 2004 Feb;74(2):326-37. Epub 2004 Jan 22.

Supplemental Content

Loading ...
Support Center